Experts highlighted the government and policy makers in a panel discussion 2025 Bioasia in Hyderabad on Wednesday, in a panel discussion entitled “Clinical Trials – Great Opportunities in India and How to Capture the Market” , role in strengthening India’s participation in clinical trials. |Picture source: Special arrangement
During a panel discussion on BioAsia 2025 in Hyderabad on Wednesday, experts highlighted the key role of government and policy makers in enhancing India’s participation in clinical trials. Despite bearing 15% of the global disease burden, less than 3% of the world clinical trials in India have attracted attention due to the limited contribution of the country to global clinical research, experts said.
In a panel discussion by Smruthi Suryaprakash, partner at BCG India, titled “Clinical Trials – Great Opportunities in India and How to Capture the Market”, noting that India’s diverse population is an important asset for clinical trials, providing researchers with a richness Access to the dataset. She stressed that the country has top hospitals and expanding Global Capacity Center (GCC) infrastructure, which positioned it well for large-scale clinical trials. However, she noted that the shift in public perception is crucial, as many Indians still view clinical trials as the fundamental pillar of medical research.
“India’s early narratives around multinational corporations have hindered its growth as a clinical trial center,” said Sadhna Joglekar of the Novartis Development Project in India. She noted that neighboring countries such as South Korea and Malaysia have successfully developed ecosystems that are conducive to clinical research through strong government initiatives, attracting global trials from India.
Sanjay Vyas, President and Global President of Safety Services and Clinical Logistics at Parexel International, stressed that India needs to recognize the long-term benefits of clinical trials, especially in improving patients’ use of cutting-edge drugs. He stressed that despite India’s active participation in the Phase 2, Phase 3 and Phase 4 trials, the potential potential has not been developed in the Phase 1 trials, which is currently conducted on a limited basis. He noted that new drug molecules developed outside India have not yet conducted initial phase trials in the country, which is a big missed opportunity.
Group members jointly urge policy makers to create a more research-friendly regulatory environment, promote trust in clinical trials, and encourage investment in early stage drug development.
publishing – February 26, 2025 at 07:09 pm IST
